Achieve Life Sciences Inc.

NASDAQ: ACHV    
Share price (4/26/24): $4.61    
Market cap (4/26/24): $158 million
Search in Documents
Key Exhibits
External Links
1 Achieve Life Sciences Inc. Expert Interviews, now on BamSEC.
 Powered by Tegus.

Material Contracts Filter

EX-10.32
from 10-K 10 pages Renewal Service Agreement Agreement Date: November 9, 2023
12/34/56
EX-10.21
from 10-K 20 pages Dated 14 May 2015 (1) Extab Pharma, Inc. and (2) Sopharma Ad Share Purchase Agreement 1 Contents
12/34/56
EX-10.10
from 10-K 7 pages Indemnification Agreement
12/34/56
EX-10.1
from 8-K 43 pages Securities Purchase Agreement
12/34/56
EX-10.1
from 8-K 35 pages Securities Purchase Agreement
12/34/56
EX-10.2
from 8-K 24 pages Registration Rights Agreement
12/34/56
EX-10.1
from 8-K 75 pages 2023 Contingent Convertible Debt Agreement
12/34/56
EX-10.1
from 8-K 4 pages Achieve Life Sciences, Inc. 1040 West Georgia Street, Suite 1030 Vancouver, Bc V6e 4h1
12/34/56
EX-10.26
from 10-K 9 pages Amended and Restated Employment Agreement
12/34/56
EX-10.22
from 10-K 5 pages Lease Extension Agreement
12/34/56
EX-10.8
from 10-K 49 pages Achieve Life Sciences, Inc. 2018 Equity Incentive Plan
12/34/56
EX-10.1
from 8-K 10 pages Achieve Life Sciences, Inc. 1040 West Georgia Street, Suite 1030 Vancouver, Bc V6e 4h1
12/34/56
EX-10.2
from 8-K 18 pages Registration Rights Agreement
12/34/56
EX-10.1
from 8-K 12 pages Subscription Agreement
12/34/56
EX-10.2
from 8-K 6 pages First Amendment to 2021 Contingent Convertible Debt Agreement
12/34/56
EX-10.2
from 8-K 23 pages Registration Rights Agreement
12/34/56
EX-10.1
from 8-K 67 pages 2021 Contingent Convertible Debt Agreement
12/34/56
EX-10.4
from 10-Q 9 pages Amended and Restated Employment Agreement
12/34/56
EX-10.3
from 10-Q 9 pages Amended and Restated Employment Agreement
12/34/56
EX-10.2
from 10-Q 2 pages Anthony Clarke September 28, 2020 Dear Anthony Background Amendments to Contract 1. Position Clause 1.1 the Current Clause 1.1 Shall Be Deleted and Replaced With the Following: "Your Title Will Be Chief Scientific Officer. You Shall Report Directly to the Chief Executive Officer of the Company. You Shall Have Such Duties, Authority and Responsibilities as Are Commensurate With Being Chief Scientific Officer of the Company." Clause 1.3 the Current Clause 1.3(c) – (F) (Inclusive) and Clause 1.3(h) – (I) Shall Be Deleted. 2. Compensation Clause 2.1 the Current Clause 2.1 Shall Be Deleted and Replaced With the Following: "The Company Will Pay You a Salary at the Rate of $120,000 Usd Per Year Which Shall Accrue Day to Day and Be Payable in Equal Monthly Instalments in Arrears in Accordance With the Company's Standard Payroll Schedule. Your Salary Will Be Subject to Annual Review."
12/34/56